Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features

The treatment of stage III NSCLC involves a multi-disciplinary approach and careful patient selection to determine which resectable patients might benefit from a trimodality treatment [1,2]. Neoadjuvant chemotherapy administered prior to surgery can reduce tumor extent and metastases, thereby improving resectability. The role of surgery in stage IIIA patients still remains controversial. Survival benefit of surgery in this setting has long been debated and has proven difficult to demonstrate in multi-institute trials compared to definitive chemoradiation [1,3].

Source: Lung Cancer - July 4, 2019 Category: Cancer & Oncology Authors: Mohammadhadi Khorrami, Prantesh Jain, Kaustav Bera, Pradnya Patil, Usman Ahmad, Sudish Murthy, Kevin Stephans, Pingfu Fu, Vamsidhar Velcheti, Anant Madabhushi Source Type: research